{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:26:18Z","timestamp":1790807178168,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41431-024-01645-4","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:21:54Z","timestamp":1719429714000},"page":"1559-1566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical spectrum of rare bone fragility disorders and response to bisphosphonate treatment: a retrospective study"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7091-3799","authenticated-orcid":false,"given":"Ma\u00eblle","family":"Charpi\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Baujat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1497-9363","authenticated-orcid":false,"given":"Julien","family":"Van Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Leheup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lise","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e9nie","family":"Koumakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zagorka","family":"Pejin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Monnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2839-9856","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Cormier-Daire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"1645_CR1","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00198-016-3709-1","volume":"27","author":"G Bardai","year":"2016","unstructured":"Bardai G, Moffatt P, Glorieux FH, Rauch F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteoporos Int 2016;27:3607\u201313.","journal-title":"Osteoporos Int"},{"key":"1645_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","volume":"51","author":"H Castillo","year":"2009","unstructured":"Castillo H, Samson-Fang L. American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 2009;51:17\u201329.","journal-title":"Dev Med Child Neurol"},{"key":"1645_CR3","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/jbmr.2567","volume":"30","author":"T Palomo","year":"2015","unstructured":"Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, et al. Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res. 2015;30:2150\u20137.","journal-title":"J Bone Miner Res"},{"key":"1645_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/adc.2003.036590","volume":"90","author":"NJ Shaw","year":"2005","unstructured":"Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005;90:494\u20139.","journal-title":"Arch Dis Child"},{"key":"1645_CR5","doi-asserted-by":"crossref","unstructured":"Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin. Orthop. Relat. Res. 1981;111\u201322.","DOI":"10.1097\/00003086-198109000-00015"},{"key":"1645_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","volume":"127","author":"R Morello","year":"2006","unstructured":"Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006;127:291\u2013304.","journal-title":"Cell"},{"key":"1645_CR7","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1056\/NEJMoa063804","volume":"355","author":"AM Barnes","year":"2006","unstructured":"Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N. Engl J Med. 2006;355:2757\u201364.","journal-title":"N. Engl J Med"},{"key":"1645_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00441-009-0872-0","volume":"339","author":"JC Marini","year":"2010","unstructured":"Marini JC, Cabral WA, Barnes AM. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell Tissue Res. 2010;339:59\u201370.","journal-title":"Cell Tissue Res"},{"key":"1645_CR9","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1002\/ajmg.a.34269","volume":"155A","author":"IMB Amor","year":"2011","unstructured":"Amor IMB, Rauch F, Gruenwald K, Weis M, Eyre DR, Roughley P, et al. Severe osteogenesis imperfecta caused by a small in-frame deletion in CRTAP. Am J Med Genet A. 2011;155A:2865\u201370.","journal-title":"Am J Med Genet A"},{"key":"1645_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fgene.2020.00897","volume":"11","author":"Y-A Tang","year":"2020","unstructured":"Tang Y-A, Wang L-Y, Chang C-M, Lee I-W, Tsai W-H, Sun HS. Novel compound heterozygous mutations in cause rare autosomal recessive osteogenesis imperfecta. Front Genet. 2020;11:897.","journal-title":"Front Genet"},{"key":"1645_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17:30\u20138.","journal-title":"J Bone Miner Res"},{"key":"1645_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","volume":"88","author":"J Becker","year":"2011","unstructured":"Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011;88:362\u201371.","journal-title":"Am J Hum Genet"},{"key":"1645_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/jbmr.1480","volume":"27","author":"G Venturi","year":"2012","unstructured":"Venturi G, Gandini A, Monti E, Dalle Carbonare L, Corradi M, et al. Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor, causes progressively deforming osteogenesis imperfecta with normal type I collagen. J Bone Miner Res. 2012;27:723\u20138.","journal-title":"J Bone Miner Res"},{"key":"1645_CR14","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1002\/jbmr.487","volume":"26","author":"EP Homan","year":"2011","unstructured":"Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, et al. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res. 2011;26:2798\u2013803.","journal-title":"J Bone Miner Res"},{"key":"1645_CR15","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/ajmg.a.35938","volume":"161A","author":"JA Caparr\u00f3s-Martin","year":"2013","unstructured":"Caparr\u00f3s-Martin JA, Valencia M, Pulido V, Mart\u00ednez-Glez V, Rueda-Arenas I, Amr K, et al. Clinical and molecular analysis in families with autosomal recessive osteogenesis imperfecta identifies mutations in five genes and suggests genotype-phenotype correlations. Am J Med Genet A. 2013;161A:1354\u201369.","journal-title":"Am J Med Genet A"},{"key":"1645_CR16","first-page":"235","volume":"2","author":"Z Jin","year":"2018","unstructured":"Jin Z, Burrage LC, Jiang M-M, Lee Y-C, Bertin T, Chen Y, et al. Whole-exome sequencing identifies an intronic cryptic splice site in causing osteogenesis imperfecta type VI. JBMR. 2018;2:235\u20139.","journal-title":"JBMR"},{"key":"1645_CR17","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00198-017-4141-x","volume":"28","author":"P Trejo","year":"2017","unstructured":"Trejo P, Palomo T, Montpetit K, Fassier F, Sato A, Glorieux FH, et al. Long-term follow-up in osteogenesis imperfecta type VI. Osteoporos Int. 2017;28:2975\u201383.","journal-title":"Osteoporos Int"},{"key":"1645_CR18","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1515\/jpem-2020-0260","volume":"33","author":"NB Celik","year":"2020","unstructured":"Celik NB, Gonc N, Ozon A, Alikasifoglu A, Rauch F, Kandemir N. Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter? J Pediatr Endocrinol Metab. 2020;33:1617\u201324.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1645_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000369108","volume":"5","author":"RM Minillo","year":"2014","unstructured":"Minillo RM, Sobreira N, de Faria Soares M, de F, Jurgens J, Ling H, et al. Novel deletion of SERPINF1 causes autosomal recessive osteogenesis imperfecta type VI in two Brazilian families. Mol Syndromol. 2014;5:268\u201375.","journal-title":"Mol Syndromol"},{"key":"1645_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0145-1","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O. Two years\u2019 experience with denosumab for children with osteogenesis imperfecta Type VI. Orphanet J Rare Dis. 2014;9:145.","journal-title":"Orphanet J Rare Dis"},{"key":"1645_CR21","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/ajmg.a.35319","volume":"158A","author":"T Tucker","year":"2012","unstructured":"Tucker T, Nelson T, Sirrs S, Roughley P, Glorieux FH, Moffatt P, et al. A co-occurrence of osteogenesis imperfecta type VI and cystinosis. Am J Med Genet A. 2012;158A:1422\u20136.","journal-title":"Am J Med Genet A"},{"key":"1645_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3346\/jkms.2013.28.7.1107","volume":"28","author":"SY Cho","year":"2013","unstructured":"Cho SY, Ki C-S, Sohn YB, Kim SJ, Maeng SH, Jin D-K. Osteogenesis imperfecta Type VI with severe bony deformities caused by novel compound heterozygous mutations in SERPINF1. J Korean Med Sci. 2013;28:1107\u201310.","journal-title":"J Korean Med Sci"},{"key":"1645_CR23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","volume":"40","author":"C Land","year":"2007","unstructured":"Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous Pamidronate treatment. Bone. 2007;40:638\u201344.","journal-title":"Bone"},{"key":"1645_CR24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/jbmr.4011","volume":"35","author":"J Dubail","year":"2020","unstructured":"Dubail J, Brunelle P, Baujat G, Huber C, Doyard M, Michot C, et al. Homozygous loss-of-function mutations in CCDC134 are responsible for a severe form of osteogenesis imperfecta. J Bone Miner Res. 2020;35:1470\u201380.","journal-title":"J Bone Miner Res"},{"key":"1645_CR25","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363:1427\u201331.","journal-title":"Lancet"},{"key":"1645_CR26","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","volume":"382","author":"N Bishop","year":"2013","unstructured":"Bishop N, Adami S, Ahmed SF, Ant\u00f3n J, Arundel P, Burren CP, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1424\u201332.","journal-title":"Lancet"},{"key":"1645_CR27","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1002\/jbmr.3833","volume":"34","author":"M-E Robinson","year":"2019","unstructured":"Robinson M-E, Trejo P, Palomo T, Glorieux FH, Rauch F. Osteogenesis imperfecta: skeletal outcomes after bisphosphonate discontinuation at final height. J Bone Miner Res. 2019;34:2198\u2013204.","journal-title":"J Bone Miner Res"},{"key":"1645_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/BPO.0b013e318173a923","volume":"28","author":"S Poyrazoglu","year":"2008","unstructured":"Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F, Eryilmaz SK, et al. Successful results of Pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop. 2008;28:483\u20137.","journal-title":"J Pediatr Orthop"},{"key":"1645_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2016.02.015","volume":"87","author":"K Lindahl","year":"2016","unstructured":"Lindahl K, Kindmark A, Rubin C-J, Malmgren B, Grigelioniene G, S\u00f6derh\u00e4ll S, et al. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Bone. 2016;87:11\u20138.","journal-title":"Bone"},{"key":"1645_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12887-020-02491-1","volume":"21","author":"P Mohsenzade","year":"2021","unstructured":"Mohsenzade P, Amirhakimi A, Honar N, Saki F, Omrani GHR, Dabbaghmanesh M. Bone density, fractures and the associated factors in iranian children and adolescent with Osteogenesis Imperfecta. BMC Pediatr. 2021;21:37.","journal-title":"BMC Pediatr"},{"key":"1645_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1440-1754.2005.00567.x","volume":"41","author":"F Fleming","year":"2005","unstructured":"Fleming F, Woodhead HJ, Briody JN, Hall J, Cowell CT, Ault J, et al. Cyclic bisphosphonate therapy in osteogenesis imperfecta type V. J Paediatr Child Health 2005;41:147\u201351.","journal-title":"J Paediatr Child Health"},{"key":"1645_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bone.2005.07.020","volume":"38","author":"L Zeitlin","year":"2006","unstructured":"Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH. The effect of cyclical intravenous Pamidronate in children and adolescents with osteogenesis imperfecta type V. Bone. 2006;38:13\u201320.","journal-title":"Bone"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01645-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01645-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01645-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T14:02:51Z","timestamp":1732888971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01645-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1038\/s41431-024-01645-4","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the CER APHP ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}